Answers are grounded in this paper and cite their sources.
INTRODUCTION: Smoking is associated with poor prognosis and distinct molecular alterations in CRC, but its prognostic significance across different treatment-exposed populations remains unclear. We comprehensively investigated the clinicopathological, genomic, and treatment-specific prognostic significance of smoking in CRC using large public datasets. METHODS: Clinicopathological, genomic, treatment, and survival data were obtained from the MSK-CHORD 2024 and MSK-IMPACT 50K databases. Patients were classified as smokers or non-smokers. Associations between smoking history, genomic alterations, mutation clonality, and overall survival (OS) were evaluated. Independent prognostic factors were identified using multivariable Cox regression analyses. RESULTS: Smokers were older, more frequently male, and had poorer baseline performance status than non-smokers. Smoking was independently associated with worse OS in the overall cohort and among patients exposed to oxaliplatin-, irinotecan-, and EGFR-targeted therapies, but not among those exposed to VEGF-targeted therapy or immune checkpoint inhibitors. Genomic analyses demonstrated that BRAF mutations and FGFR1 copy number amplifications (CNAs) were significantly enriched in smokers, whereas TCF7L2 mutations were more frequent in non-smokers. Although the overall distribution of BRAF clonality categories differed significantly according to smoking status, this difference was not statistically significant among BRAF-mutant tumors. CONCLUSIONS: Smoking history was independently associated with poor prognosis in patients with CRC including among patients exposed to oxaliplatin-, irinotecan-, and EGFR-targeted therapies. Additionally, smokers exhibited distinct genomic characteristics, including higher frequencies of BRAF mutations and FGFR1 CNAs. These findings provide new insights into the clinical and molecular characteristics associated with smoking in CRC and warrant further validation in clinically annotated cohorts.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: